ABSTRACT. To investigate potency of oral disulfiram (DSF) compared with that of dexamethasone (Dexa), on endotoxin-induced uveitis (EIU) in rats. The oral administration with 750 mg/kg DSF suppressed the number of inflammatory cells, protein concentration, and levels of tumor necrosis factor (TNF)-, Nitric oxide (NO) and prostaglandin (PG) E2 in the aqueous humor and improved the histiologic status of the ocular tissue at 24 hr after lipopolysaccharide (LPS) injection. The anti-inflammatory potency of DSF oral administration was as strong as that observed with 0.5 mg/kg Dexa in the present study. The results suggest that DSF might pave the way for a novel therapeutic agent for the management of uveitis.
Endotoxin-induced uveitis (EIU) is an animal model for acute ocular inflammation [17] . In general, cellular inflammation in EIU starts 4 hr after injection of LPS, with maximum infiltration after 18-24 hr [24] . The Although the contributions of tumor necrosis factor (TNF)-α are pleiotropic [10, 16, 18] , the TNF-α, Interleukin (IL)-1β and IL-6 are considered to be particularly essential in the pathogenesis of EIU [3, 4, 25] . Nitric oxide (NO) [8] and prostaglandin (PG) E2 [1] are also involved in the pathogenesis of EIU. Disulfirum (DSF), as a prodrug of diethyldithiocarbamate (DDC), has long been used for the treatment of alcoholic syndrome without severe side effects [14] . DSF is cleaved into DDC within the gastrointestinal tract by oral administration. DSF has been reported to have multiple biological properties, including anti-inflammatory [23] , anti-cataract [7] , and anti-tumor properties [2] . We previously reported that oral DSF administration significantly reduced the development of EIU in a dose-dependent manner and 750 mg/kg DSF was most effective in inhibiting LPS-induced elevation of number of infiltrating cells, protein concentration and inflammatory mediators in aqueous humor [9] , but did not compare DSF with corticosteroids which was the primary treatments available for uveitis. In our present study, therefore, we focused our attention on the antiinflammatory potency of 750 mg/kg DSF compared with that of 0.5 mg/kg dexamethasone (Dexa).
Seven-week-old male Lewis rats were used. The rats weighed 180-220 g. After appropriately anesthetized with isoflurane, EIU was induced by injection into one footpad of 200 μg of LPS from Salmonella typhimurium (Sigma-Aldrich, St. Louis, MO, U.S.A.) that had been diluted in 0.1 ml of phosphate buffered saline (pH 7.4 PBS). Rats were orally administered 750 mg/kg of DSF (Sigma-Aldrich) diluted in 0.4 ml of 0.5% w/v dimethyl sulfoxide (DMSO; Sigma-Aldrich). DSF was orally administered 1 hr prior to LPS injection via gastic gavage. For the LPS and control group, 0.4 ml of 0.5% w/v DMSO was given orally on the same schedule as the DSF group. Dexa was administered in rats as described previously [15] . Briefly, animals were systemically treated with Dexa (subcutaneously in the posterior neck region) 4 hr before LPS. In preliminary study about the dose of Dexa, either 0.2, 0.5 or 1.0 mg/kg Dexa was injected subcutaneously, and the effect of 0.5 mg/kg Dexa on the number of infiltrating cells and protein concentration in aqueous humor was almost the same as that for the 750 mg/kg DSF group (data not shown). In our present study, therefore, 0.5 mg/kg Dexa was injected 4 hr before LPS. Animals were handled and cared for according to the ARVO statement on the Use of Animals in Ophthalmic and Vision Research. The rats were euthanized 24 hr after LPS injection, and the aqueous humor (20-25 μl/rat) was collected from both eyes immediately by an anterior chamber puncture using a 30-gauge needle under a surgical microscope. For cell counting, the aqueous humor was suspended in an equal amount of Türk stain solution, and the cells were counted using a hemocytometer under light microscopy. The number of cells per field (an equivalent of 0.1 μl) was obtained by averaging the results of four fields from each sample. The aqueous humor samples were then centrifuged at 2,500 rpm for 5 min at 4C to obtain the supernatant. The total protein concentration in the aqueous humor samples was measured with a bicinchonmic acid (BCA) protein assay kit (Pierce, Rockford, IL, U.S.A.).
Twenty-four hours after LPS injection, rats were deeply anesthetized with isoflurane and the eyes were fixed by an intracardiac perfusion of 4% cold paraformaldehyde in The total level of nitrate plus nitrite in the aqueous humor was measured by using a total nitrite colorimetric assay kit (Oxis International, Portland, OR, U.S.A.) according to the manufacturer's instruction. The levels of TNF-α and PGE2 in the aqueous humor were assessed using a commercially available enzyme-linked immunosorbent assay kit (TNF-α and PGE2: R&D Systems, Minneapolis, MN, U.S.A.) according to the manufacturer's instructions.
All data are expressed as mean  SD. Parametric data were analyzed by variance (ANOVA) and the Tukey test was used for ad hoc comparison between the two treatment groups. Non-parametric data were analyzed by KruskalWallis, and the Newman-Keuls test was used for ad hoc comparison to between the two treatment groups. P<0.05 was considered to be statistically significant.
In this study, the clinical onset of EIU was observed 18 to 24 hr after LPS injection. Although the movements of animals became slower for 1 hr after 750 mg/kg DSF oral administration, no other side effects or toxicity were observed for 24 hr after LPS and autopsy. In the LPS group, the number of inflammatory cells in the aqueous humor 24 hr after LPS injection, was 57.5 ± 6.6  10 5 cells/ml (mean ± SD, n=8) and the protein concentration was 28.2 ± 3.2 mg/ ml. The groups treated with DSF and Dexa showed a significantly reduced number of inflammatory cells compared with LPS group and protein concentration (P<0.001; n=8; Table 1 ). No infiltrating cells were detected in the aqueous humor of non-LPS injection rats (control group) and the level of protein detectable was 1.0 ± 0.2 mg/ml (n=6). The effect of 750 mg/kg DSF on the aqueous humor cell number and protein concentration did not differ significantly from that of 0.5 mg/kg Dexa effect. The mean of histopathologic grading in the LPS group was 2.8 ± 0.3. The histological findings in the groups treated with DSF and Dexa showed significantly lower grading compared to the LPS group (P<0.01; n=8; Fig. 1B) . Treatment with DSF showed no significant difference from that of Dexa group. Considerable production of NO, TNF-α and PGE2 in the aqueous humor was seen in LPS group. DSF and Dexa treatment significantly reduced their concentrations in aqueous humor (P<0.001; n=8; Table 2 ). There was no significant difference between the levels of NO, PGE2 and TNF-α in the DSF group and the Dexa group.
In this study, 750 mg/kg DSF and 0.5 mg/kg Dexa reduced LPS-induced infiltrating cells, protein concentration, TNF-α, NO and PGE2 levels in aqueous humor as well as histopathologic manifestation of EIU. The anti-inflammatory potency of DSF oral administration was as strong as that observed with Dexa. The treatment available for uveitis primarily includes corticosteroids, with suggested topical or systemic application. However, corticosteroids have severe side effects and may cause cataract, glaucoma, and susceptibility to microbial infections and may decrease patient quality of life [5] . Given these restrictions, there is an obvious demand for the development of new therapeutic strategies. Indeed, many alternative approaches, including antioxidants [11, 12, 26] and anticytokine therapies (such as anti-TNF) have been shown to prevent ocular inflammation in experimental animals [11, 12] . DSF has long been used to treat alchoholic syndrome without severe side effects [14] . DSF is a powerful antioxidant that scavenges reactive oxygen species such as hydroxyl radical, superoxide anion, and peroxynitrite, and is an inhibitor of NF-κB [20] . The LD 50 of DSF given orally in rats and dogs are 8.6 and 3.5 g/kg, respectively. Although the movements of animals became slower for 1 hr after 750 mg/kg DSF oral administration, no other side effects or toxicity were observed for 24 hr after LPS and autopsy. However, the clinical dose for an adult human is typically 100-500 mg/day DSF. If one assumes that the human is 70 kg then the dose would be under 10 mg/ kg/day for use in alcohol treatment. Consequently, one potential problems for the clinical use of oral (systemic) DSF administration as an anti-inflammatory drug might be the relatively high doses required for strong anti-inflammatory effects compared with Dexa and might be the side effects induced by medium and long term administrations of high doses of DSF. Ishiyama et al. reported that over 800 mg/kg DDC treatment showed remarkable elevation of plasma transaminase activities and histologically, submassive necrosis in the liver after 24 hr in rats [6] . In addition, nurotoxic effects have been reported after high doses of oral DSF treatment (580 mg/kg/day DSF for three weeks) in rats [19] . While studies on side effects in humans during long term administration of high doses of DSF and DDC are not yet available, short term treatment with intravenous infusion of up to 150 mg/kg/day DDC was tolerated by cancer human patients [13] . In addition, over 500 patients with nickel carbonyl poisoning have received DDC both orally and parenterally at doses up to 25 mg/kg/day without occurrence of toxicity [21, 22] . To overcome this problem, we expected that the application of DSF eyedrops was an effective approach, and our further experiments demonstrated instillation of 0.5% DSF eyedrops (DSF and hydroxypropyl-β-cyclodextrin inclusion complex) were as strong as that observed with 0.05% Dexa on the same schedule as DSF eyedrops (unpublished data).
In conclusion, this study suggests that the anti-inflammatory potency of 750 mg/kg DSF oral administration was as strong as that observed with 0.5 mg/kg Dexa. The results suggest that DSF might pave the way for a novel therapeutic agent for the management of ocular inflammation. 
